{"id":"W4417012274","doi":"10.1182/blood-2025-3735","title":"Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Saskatchewan Cancer Agency; University of Saskatchewan; McGill University; Jewish General Hospital","funders":"","keywords":"Clinical endpoint; Follicular lymphoma; Refractory (planetary science); Regimen; Phases of clinical research; Salvage therapy; Lymphoma; Combination therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001773329,0.0006388954,0.00144317,0.0003178829,0.0004281603,0.001224381,0.00050326,0.0005587267,0.001329525],"category_scores_gemma":[0.0007097705,0.0002770202,0.0009998288,0.0004002539,0.0004272741,0.0006748372,0.0002344177,0.001630041,0.0004927234],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008550077,"about_ca_system_score_gemma":0.0006375569,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007080947,"about_ca_topic_score_gemma":0.001848869,"domain_scores_codex":[0.9994816,0.0001625208,0.00004527351,0.00009268858,0.00008486211,0.0001331097],"domain_scores_gemma":[0.9993076,0.0001183601,0.0001620244,0.00008819765,0.00005930794,0.0002645174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3160235,0.03167957,0.1100207,0.0008492707,0.004910556,0.0007746795,0.0005651915,0.003283107,0.1096434,0.0002244213,0.007628206,0.4143974],"study_design_scores_gemma":[0.1194905,0.495706,0.3448606,0.0001361452,0.003539382,0.001873069,0.0002382718,0.003381365,0.01716914,0.0003242112,0.01320989,0.00007140425],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938295,0.003260372,0.0004103753,0.0001609527,0.0000355804,0.0003030929,0.0005814407,0.00005825641,0.001360415],"genre_scores_gemma":[0.996801,0.0007199303,0.000280442,0.0002885189,0.0000375659,0.0001504794,0.001190058,0.00001141217,0.0005205796],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001773329,"threshold_uncertainty_score":0.009378374,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01122149466872017,"score_gpt":0.2776723305511716,"score_spread":0.2664508358824514,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}